Larimar Therapeutics Target of Unusually Large Options Trading (NASDAQ:LRMR)

Larimar Therapeutics, Inc. (NASDAQ:LRMR) was the recipient of unusually large options trading activity on Wednesday. Investors purchased 3,744 call options on the company. This represents an increase of approximately 456% compared to the average volume of 673 call options.

Institutional Trading of Larimar Therapeutics

Hedge funds have recently made changes to their positions in the company. XTX Topco Ltd increased its stake in shares of Larimar Therapeutics by 127.1% in the fourth quarter. XTX Topco Ltd now owns 118,938 shares of the company’s stock valued at $453,000 after buying an additional 66,569 shares during the period. Quadrature Capital Ltd grew its holdings in Larimar Therapeutics by 195.4% during the 4th quarter. Quadrature Capital Ltd now owns 57,646 shares of the company’s stock worth $220,000 after acquiring an additional 38,131 shares during the last quarter. Millennium Management LLC increased its position in Larimar Therapeutics by 7.2% in the 4th quarter. Millennium Management LLC now owns 5,206,364 shares of the company’s stock valued at $19,836,000 after acquiring an additional 349,533 shares during the period. Man Group plc acquired a new position in Larimar Therapeutics in the 4th quarter valued at approximately $149,000. Finally, Bridgeway Capital Management LLC raised its stake in shares of Larimar Therapeutics by 42.2% during the fourth quarter. Bridgeway Capital Management LLC now owns 111,216 shares of the company’s stock valued at $424,000 after acquiring an additional 33,000 shares during the last quarter. 91.92% of the stock is owned by institutional investors and hedge funds.

Larimar Therapeutics News Summary

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia and Larimar says topline open‑label data will support a BLA planned for June 2026; company targets a potential U.S. launch in H1 2027. This is the primary fundamental catalyst driving the move. Article Title
• Positive Sentiment: Wedbush reaffirmed an “outperform” rating and set an $11 price target, implying significant upside versus recent levels — a clear analyst vote of confidence that likely supported buying. Article Title
• Positive Sentiment: Lifesci Capital upgraded LRMR to “strong‑buy,” another bullish analyst action adding to demand from institutional and retail investors. Article Title
• Neutral Sentiment: Multiple outlets reported the stock surge and the FDA news, increasing visibility and trading volume (coverage from Investing.com, MSN and AAII). Media amplification can prolong momentum but doesn’t change the underlying clinical/regulatory timeline. Article Title Article Title Article Title Article Title

Larimar Therapeutics Stock Performance

Shares of Larimar Therapeutics stock traded up $1.71 during midday trading on Wednesday, hitting $5.40. 22,869,448 shares of the company traded hands, compared to its average volume of 3,283,496. The firm’s fifty day moving average price is $3.44 and its 200-day moving average price is $3.76. The stock has a market cap of $447.17 million, a price-to-earnings ratio of -2.81 and a beta of 1.01. Larimar Therapeutics has a 12 month low of $1.61 and a 12 month high of $5.47.

Analysts Set New Price Targets

LRMR has been the topic of several recent analyst reports. Wedbush reissued an “outperform” rating and issued a $11.00 target price on shares of Larimar Therapeutics in a report on Wednesday. Leerink Partners raised shares of Larimar Therapeutics to a “strong-buy” rating in a research note on Monday, January 5th. Lifesci Capital upgraded shares of Larimar Therapeutics to a “strong-buy” rating in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $16.50.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.